Dr. Tagawa on pivotal trials supporting use of 177Lu-PSMA-617 in prostate cancer

Video

Scott T. Tagawa, MD, MS, FACP, discusses the pivotal VISION and TheraP trials that supported the FDA approval of 177Lu-PSMA-617 (lutetium Lu 177 vipivotide tetraxetan; Pluvicto) for the treatment of patients with PSMA-positive metastatic castration-resistant prostate cancer in the post androgen receptor pathway inhibition, post taxane-based chemotherapy setting. Tagawa is a professor of clinical medicine and clinical urology and medical director of the Genitourinary Oncology Research Program at Weill Cornell Medicine in New York City. He is also an assistant attending physician on the Cornell campus at New York-Presbyterian Hospital.

Related Videos
Prostate cancer cell division | Image Credit: © PRB ARTS - stock.adobe.com
Group of doctors reading a document | Image Credit: © Flamingo Images - stock.adobe.com
Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Leonardo Kayat Bittencourt, MD, PhD, answers a question during a Zoom video interview
Lab with MRI machine | Image Credit: © phonlamaiphoto - stock.adobe.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.